Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Plain-language summary

The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123 iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.

What this study adds

Evidence grade: High

This is a narrative review. This 2017 consensus report from the DLB Consortium updates its earlier, widely used criteria for diagnosing dementia with Lewy bodies. It separates clinical features from diagnostic biomarkers, gives more weight to REM sleep behavior disorder and MIBG myocardial scintigraphy, and adjusts the pathology criteria to take account of co-existing Alzheimer disease brain changes.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J. P., Weintraub, D., et al. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. https://doi.org/10.1212/wnl.0000000000004058

Vancouver

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017. doi:10.1212/wnl.0000000000004058. PMID: 28592453.

BibTeX

@article{mckeith2017-28592453,
  author  = {McKeith, I. G. and Boeve, B. F. and Dickson, D. W. and Halliday, G. and Taylor, J. P. and Weintraub, D. and Aarsland, D. and Galvin, J. and others},
  title   = {{Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium}},
  journal = {Neurology},
  year    = {2017},
  doi     = {10.1212/wnl.0000000000004058},
  pmid    = {28592453},
  url     = {https://doi.org/10.1212/wnl.0000000000004058}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This 2017 consensus report from the DLB Consortium updates its earlier, widely used criteria for diagnosing dementia with Lewy bodies. It separates clinical features from diagnostic biomarkers, gives more weight to REM sleep behavior disorder and MIBG myocardial scintigraphy, and adjusts the pathology criteria to take account of co-existing Alzheimer disease brain changes. It states that its treatment recommendations are largely based on expert opinion because randomized controlled trials in DLB are few.

Study details

How this study scored 67/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 6 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 65 of the 97 points it could be judged on, which is 67 of 100. Total 67 of 100.65 of the 97 points we could judge = 67 of 100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 65 of the 97 points we could judge it on, which is 67 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2017 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 4,467 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 406.1 citations a year over 11 year(s) since 2017
Impact for its field and year 6 / 6 Cited 187.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 6 / 6 Cited by 250 other studies in this library
Still being cited 4 / 4 Cited 1,591 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Kenji Kosaka: h-index 61 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 28592453)
Free to read 2 / 2 Free to read
Points 65 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 65 of the 97 points we could judge it on is 67 out of 100.
Total 67 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 43.

Later studies that cite this one

260 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →